Ascendis Pharma stock

ASND · NASDAQ · USD

Compare Ascendis Pharma
$275.39Change from previous close: +3.12%Absolute change: +$8.32

Close · November 13, 2026

Price history

+33.39% over the period

1 year: from $206.45 (November 13, 2025) to $275.39 (November 13, 2026), +33.39%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$275.39
October 30, 2026$251.27
September 30, 2026$227.83
August 31, 2026$263.04
July 31, 2026$243.91
June 30, 2026$266.72
May 29, 2026$224.11
April 30, 2026$229.38
March 31, 2026$228.73
February 27, 2026$233.50
January 30, 2026$226.10
December 31, 2025$213.24
November 28, 2025$212.33
November 13, 2025$206.45

At a glance

  • The company

    Biopharmaceutical company developing TransCon-based therapies for rare endocrine diseases and oncology indications

  • Latest results

    Quarter to September 30, 2026 · EPS €1.71 (estimate €0.80)

TickerLandia's take on Ascendis Pharma

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$188.08
52-wk high$282.15

−2.40% from the 52-week high

Analysts · 21 analysts

Average target$315.20+14.46% vs. price

Buy 20 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Ascendis Pharma

Compared with similar companies: very low earnings stability and very high profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Ascendis Pharma is cheaper than similar companies

Ascendis Pharma's P/E (trailing 12 months): 18.1, −28% against the median of a group of 7 similar companies (25.1).

Compared with 7 similar companies

Ascendis Pharma's metrics compared with similar companies
MetricAscendis PharmaPosition in the groupBand
P/E (trailing 12 months)18.1Low
Forward P/E22.9Middle
Operating margin30.9%Middle
ROE132.2%High
Debt/equity0.30Middle

Grey band: the middle half of the group; tick: the median; dot: Ascendis Pharma. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€339.29M

Latest quarter · Q2 2026

Net income

€206.97M

Latest quarter · Q2 2026

Quarterly net margin

61.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$18.06B
P/E
18.1
EPS
$15.21
Volume
826.04K
Daily trading
€159.99M
Dividend yield
0.00%

How Ascendis Pharma is changing

All results
  • Revenue grew 153.0% a year on average over the last 5 years

  • Operating margin rose from −1,097.9% to −18.9%

  • Shares outstanding up 19.7% in 5 years

Returns

Ascendis Pharma returns

$1,000 invested in Ascendis Pharma 5 years ago, on November 15, 2021, would be worth $1,798 today: +79.83% in total, +12.47% per year. This is the price return only: dividends are excluded.

PeriodAscendis PharmaS&P 500$1,000 becomes
1 month+23.38%−3.12%$1,234
6 months+13.06%+1.58%$1,131
Year to date+29.15%+10.46%$1,291
1 year+33.39%+12.23%$1,334
3 years+207.94%+71.41%$3,079
5 years+79.83%+61.48%$1,798
10 years+1,253.93%+249.40%$13,539

Over the last 6 months it has done better than 41% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Ascendis Pharma: technical analysis

Ascendis Pharma is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 0.6% below its all-time closing high ($277.18, July 8, 2026).

Trend
Upward
RSI (14 sessions)
75
Above 70: a strong rise in a short time
vs 200-session average
+14.82%

Active signals

  • Close above the high of the previous 55 sessions.

  • RSI above 70: the stock has risen a lot in a short time.

    since November 12, 2026

Support and resistance

Price areas where Ascendis Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$275.39
  3. Support$260.91−5.26%2 touches, last on August 19, 2026
  4. Support$249.17−9.52%5 touches, last on August 28, 2026
  5. Support$240.00−12.85%4 touches, last on August 14, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.40
Volatility (60 sessions, annualised)
37.3%
Largest fall in the last year
−19.66%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Ascendis Pharma: seasonality

Average monthly price change over 12 years

+3.1%Jan+5.1%Feb+3.0%Mar−3.1%Apr−0.5%May+3.5%Jun−0.7%Jul+8.4%Aug+2.5%Sep−0.0%Oct+4.7%Nov+4.2%Dec

Over the last 12 years, the strongest month for Ascendis Pharma has been August: +8.44% on average, positive in 9 years out of 12. The weakest has been April: −3.10% on average, positive in 5 years out of 12. November, the current month, has been positive in 9 years out of 11 (+4.74% on average).

Show chart data
MonthAverageMedianPositive years
January+3.13%+3.16%7 of 11
February+5.07%+2.56%7 of 12
March+3.04%−1.25%5 of 12
April−3.10%−2.75%5 of 12
May−0.51%−2.36%4 of 12
June+3.50%+2.14%8 of 12
July−0.68%+0.53%7 of 12
August+8.44%+6.20%9 of 12
September+2.53%+2.02%7 of 12
October−0.04%−0.87%6 of 12
November+4.74%+5.32%9 of 11
December+4.20%+0.43%6 of 11

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Ascendis Pharma and its competitors

Founded in 2006, Ascendis Pharma A/S is based in Hellerup, Denmark, and develops therapies built on its TransCon technology for rare conditions with unmet medical needs in Europe, the United States and other markets. Its marketed products include SKYTROFA, prescribed to children with growth hormone shortfall, and YORVIPATH, a daily subcutaneous injection for adults with chronic hypoparathyroidism. The company also has three endocrinology rare disease candidates in clinical development and advances oncology candidates.

Headquarters
Hellerup, Denmark
Employees
1,189
Founded
2006
Chief executive
Jan Mikkelsen
Ascendis Pharma and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Ascendis PharmaASND$18.06B30.9%18.1+13.06%
ExelixisEXEL$16.84B40.2%20.7+34.53%
Jazz PharmaceuticalsJAZZ$15.5B27.4%71.5+3.97%
BioNTechBNTX$21.22B-55.4%—−7.19%
BridgeBio PharmaBBIO$15.25B-37.3%—+14.12%
Alnylam PharmaceuticalsALNY$22.11B19.5%8.34−43.38%

Same industry or related industries, similar size. Compare Ascendis Pharma with its competitors · Full profile